Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Goodin

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 18, 2007
Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survivalJennifer Nishioka, Susan Goodin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 18, 2006
Cancer-treatment-induced bone loss, part 1Laura Boehnke Michaud, Susan Goodin
American Journal of Clinical Oncology|December 22, 2009
Ixabepilone, a new treatment option for metastatic breast cancerDeborah L Toppmeyer, Susan Goodin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004Susan Goodin, Steven J Shiff
Clinical Therapeutics|September 23, 2008
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinasesPatrick J Medina, Susan Goodin
Pharmacotherapy|July 30, 2009
Overcoming drug resistance in patients with metastatic breast cancerSerena T Wong, Susan Goodin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 9, 2006
Cancer-treatment-induced bone loss, part 2Laura Boehnke Michaud, Susan Goodin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Cabozantinib in prostate cancer: the beginning of a precision paradigm?Susan Goodin, Robert S DiPaola
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|July 22, 2004
Conceptualization of disease timeline predicts posttreatment distress in breast cancer patientsCarolyn Rabin, Howard Leventhal, Susan Goodin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 26, 2007
Antiemetic care for patients with breast cancer: focus on drug interactions and safety concernsAngela Georgy, Jacalyn Neceskas, Susan Goodin
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 18, 2007
Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survivalJennifer Nishioka, Susan Goodin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 18, 2006
Cancer-treatment-induced bone loss, part 1Laura Boehnke Michaud, Susan Goodin
American Journal of Clinical Oncology|December 22, 2009
Ixabepilone, a new treatment option for metastatic breast cancerDeborah L Toppmeyer, Susan Goodin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
NSAIDs for the chemoprevention of oral cancer: promise or pessimism?: Commentary re J. L. Mulshine et al., randomized, double-blind, placebo-controlled, phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004Susan Goodin, Steven J Shiff
Clinical Therapeutics|September 23, 2008
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinasesPatrick J Medina, Susan Goodin
Pharmacotherapy|July 30, 2009
Overcoming drug resistance in patients with metastatic breast cancerSerena T Wong, Susan Goodin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 9, 2006
Cancer-treatment-induced bone loss, part 2Laura Boehnke Michaud, Susan Goodin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Cabozantinib in prostate cancer: the beginning of a precision paradigm?Susan Goodin, Robert S DiPaola
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|July 22, 2004
Conceptualization of disease timeline predicts posttreatment distress in breast cancer patientsCarolyn Rabin, Howard Leventhal, Susan Goodin
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 26, 2007
Antiemetic care for patients with breast cancer: focus on drug interactions and safety concernsAngela Georgy, Jacalyn Neceskas, Susan Goodin
Pageof 8